Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Journal of Infection and Chemotherapy
Published in: Journal of Infection and Chemotherapy 3/2013

01-06-2013 | Guideline

Practice guidelines for therapeutic drug monitoring of vancomycin: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring

Authors: Kazuaki Matsumoto, Yoshio Takesue, Norio Ohmagari, Takahiro Mochizuki, Hiroshige Mikamo, Masafumi Seki, Shunji Takakura, Issei Tokimatsu, Yoshiko Takahashi, Kei Kasahara, Kenji Okada, Masahiro Igarashi, Masahiro Kobayashi, Yukihiro Hamada, Masao Kimura, Yoshifumi Nishi, Yusuke Tanigawara, Toshimi Kimura

Published in: Journal of Infection and Chemotherapy | Issue 3/2013

Login to get access

Excerpt

Vancomycin (VCM) is a glycopeptide antibiotic that was introduced in Japan in November 1991. VCM is widely used for the treatment of invasive multi-resistant gram-positive bacterial infections, particularly those involving methicillin-resistant Staphylococcus aureus (MRSA) [1‐5]. VCM use is associated with adverse events, including "red man syndrome" [6], nephrotoxicity [7‐9], and ototoxicity [10, 11]. Compared with other antimicrobial agents, the therapeutic range is narrow in VCM, and therapeutic drug monitoring (TDM) is required for maximizing efficacy while minimizing the onset of these toxicities [12‐14]. …
Literature
1.
Geraci JE, Heilman FR, Nichols DR, Ross GT, Wellman WE. Some laboratory and clinical experiences with a new antibiotic, vancomycin. Proc Staff Meet Mayo Clin. 1956;31:564–82.PubMed
2.
Geraci JE, Heilman FR, Nichols DR, Wellman WE. Antibiotic therapy of bacterial endocarditis. VII. Vancomycin for acute micrococcal endocarditis; preliminary report. Proc Staff Meet Mayo Clin. 1958;33:172–81.PubMed
3.
Kirby WM, Perry DM, Bauer AW. Treatment of staphylococcal septicemia with vancomycin: report of thirty-three cases. N Engl J Med. 1960;262:49–55.PubMedCrossRef
4.
Sorrell TC, Packham DR, Shanker S, Foldes M, Munro R. Vancomycin therapy for methicillin-resistant Staphylococcus aureus. Ann Intern Med. 1982;97:344–50.PubMedCrossRef
5.
6.
Rybak MJ, Bailey EM, Warbasse LH. Absence of “red man syndrome” in patients being treated with vancomycin or high-dose teicoplanin. Antimicrob Agents Chemother. 1992;36:1204–7.PubMedCrossRef
7.
Bergman MM, Glew RH, Ebert TH. Acute interstitial nephritis associated with vancomycin therapy. Arch Intern Med. 1988;148:2139–40.PubMedCrossRef
8.
Cimino MA, Rotstein C, Slaughter RL, Emrich LJ. Relationship of serum antibiotic concentrations to nephrotoxicity in cancer patients receiving concurrent aminoglycoside and vancomycin therapy. Am J Med. 1987;83:1091–7.PubMedCrossRef
9.
Rybak MJ, Albrecht LM, Boike SC, Chandrasekar PH. Nephrotoxicity of vancomycin, alone and with an aminoglycoside. J Antimicrob Chemother. 1990;25:679–87.PubMedCrossRef
10.
Traber PG, Levine DP. Vancomycin ototoxicity in patient with normal renal function. Ann Intern Med. 1981;95:458–60.PubMedCrossRef
11.
Darko W, Medicis JJ, Smith A, Guharoy R, Lehmann DE. Mississippi mud no more: cost-effectiveness of pharmacokinetic dosage adjustment of vancomycin to prevent nephrotoxicity. Pharmacotherapy. 2003;23:643–50.PubMedCrossRef
12.
Cantú TG, Yamanaka-Yuen NA, Lietman PS. Serum vancomycin concentrations: reappraisal of their clinical value. Clin Infect Dis. 1994;18:533–43.PubMedCrossRef
13.
Brummett RE, Fox KE. Vancomycin- and erythromycin-induced hearing loss in humans. Antimicrob Agents Chemother. 1989;33:791–6.PubMedCrossRef
14.
Rybak M, Lomaestro B, Rotschafer JC, Moellering R Jr, Craig W, Billeter M, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2009;66:82–98.PubMedCrossRef
15.
Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, et al. Infectious Diseases Society of America. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011;52:e18–55.PubMedCrossRef
16.
Kobayashi M, Takesue Y, Tanigawara Y, Mikamo H, Kimura T, Hirata S, et al. Therapeutic drug monitoring survey of anti-MRSA agents in Japan. Jpn J Chemother. 2010;58:119–24.
17.
Canadian Task Force on the Periodic Health Examination. The periodic health examination. Can Med Assoc J. 1979;121:1193–254.
18.
Pritchard L, Baker C, Leggett J, Sehdev P, Brown A, Bayley KB. Increasing vancomycin serum trough concentrations and incidence of nephrotoxicity. Am J Med. 2010;123:1143–9.PubMedCrossRef
19.
Teramachi H, Hatakeyama H, Matsushita R, Imai Y, Miyamoto K, Tsuji A. Evaluation of predictability for vancomycin dosage regimens by the Bayesian method with Japanese population pharmacokinetic parameters. Biol Pharm Bull. 2002;25:1333–8.PubMedCrossRef
20.
Nunn MO, Corallo CE, Aubron C, Poole S, Dooley MJ, Cheng AC. Vancomycin dosing: assessment of time to therapeutic concentration and predictive accuracy of pharmacokinetic modeling software. Ann Pharmacother. 2011;45:757–63.PubMedCrossRef
21.
Vandecasteele SJ, De Vriese AS. Recent changes in vancomycin use in renal failure. Kidney Int. 2010;77:760–4.PubMedCrossRef
22.
Wong-Beringer A, Joo J, Tse E, Beringer P. Vancomycin-associated nephrotoxicity: a critical appraisal of risk with high-dose therapy. Int J Antimicrob Agents. 2011;37:95–101.PubMedCrossRef
23.
Niidome S, Kusano M, Karino M, Jingami S, Fukunaga E, Miyamura S, et al. Evaluation of various kidney functions equations for dose setting of vancomycin corrected by various parameters of physical constitutions. Jpn J Ther Drug Monit. 2011;28:92–101.
24.
Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet. 2004;43:925–42.PubMedCrossRef
25.
Kullar R, Davis SL, Levine DP, Rybak MJ. Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets. Clin Infect Dis. 2011;52:975–81.PubMedCrossRef
26.
27.
Forouzesh A, Moise PA, Sakoulas G. Vancomycin ototoxicity: a reevaluation in an era of increasing doses. Antimicrob Agents Chemother. 2009;53:483–6.PubMedCrossRef
28.
Winter ME. Basic principles. In: Winter ME, editor. Basic clinical pharmacokinetics. 5th ed. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins; 2010. p. 2–132.
29.
Rowland M, Tozer TN. Therapeutic regimens. In: Rowland M, Tozer TN, editors. Clinical pharmacokinetics and pharmacodynamics. Concepts and allocations. 4th ed. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins; 2011. p. 245–329.
30.
Yasuhara M, Iga T, Zenda H, Okumura K, Oguma T, Yano Y, et al. Population pharmacokinetics of vancomycin in Japanese adult patients. Ther Drug Monit. 1998;20:139–48.PubMedCrossRef
31.
Rodvold KA, Blum RA, Fischer JH, Zokufa HZ, Rotschafer JC, Crossley KB, et al. Vancomycin pharmacokinetics in patients with various degrees of renal function. Antimicrob Agents Chemother. 1988;32:848–52.PubMedCrossRef
32.
Takahashi Y, Takesue Y, Takubo S, Ishihara M, Nakajima K, Tsuchida T, et al. Preferable timing of therapeutic drug monitoring in patients with impaired renal function treated with once daily administration of vancomycin. J Infect Chemother 2013 (Epub ahead of print).
33.
Patel N, Pai MP, Rodvold KA, Lomaestro B, Drusano GL, Lodise TP. Vancomycin: we can’t get there from here. Clin Infect Dis. 2011;52:969–74.PubMedCrossRef
34.
Niki Y, Hanaki H, Matsumoto T, Yagisawa M, Kohno S, Aoki N, et al. Nationwide surveillance of bacterial respiratory pathogens conducted by the Japanese Society of Chemotherapy in 2008: general view of the pathogens’ antibacterial susceptibility. J Infect Chemother. 2011;17:510–23.PubMedCrossRef
35.
Mohr JF, Murray BE. Point: Vancomycin is not obsolete for the treatment of infection caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis. 2007;44:1536–42.PubMedCrossRef
36.
Christiansen K, Currie B, Ferguson J, Franks G, Garland S, Grayson L, et al. Therapeutic guidelines: antibiotic. 14th ed. Melbourne: Therapeutic Guidelines Limited; 2010.
37.
Howden BP, Ward PB, Charles PG, Korman TM, Fuller A, du Cros P, et al. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis. 2004;38:521–8.PubMedCrossRef
38.
Sakoulas G, Gold HS, Cohen RA, Venkataraman L, Moellering RC, Eliopoulos GM. Effects of prolonged vancomycin administration on methicillin-resistant Staphylococcus aureus (MRSA) in a patient with recurrent bacteraemia. J Antimicrob Chemother. 2006;57:699–704.PubMedCrossRef
39.
Charles PG, Ward PB, Johnson PD, Howden BP, Grayson ML. Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin Infect Dis. 2004;38:448–51.PubMedCrossRef
40.
Lodise TP, Patel N, Lomaestro BM, Rodvold KA, Drusano GL. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin Infect Dis. 2009;49:507–14.PubMedCrossRef
41.
Wunderink RG, Niederman MS, Kollef MH, Shorr AF, Kunkel MJ, Baruch A, et al. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized controlled Study. Clin Infect Dis. 2012;54:621–9.PubMedCrossRef
42.
Jeffres MN, Isakow W, Doherty JA, Micek ST, Kollef MH. A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumonia. Clin Ther. 2007;29:1107–15.PubMedCrossRef
43.
Blouin RA, Bauer LA, Miller DD, Record KE, Griffen WO Jr. Vancomycin pharmacokinetics in normal and morbidly obese subjects. Antimicrob Agents Chemother. 1982;21:575–80.PubMedCrossRef
44.
Lodise TP, Lomaestro B, Graves J, Drusano GL. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother. 2008;52:1330–6.PubMedCrossRef
45.
Itani KM, Biswas P, Reisman A, Bhattacharyya H, Baruch AM. Clinical efficacy of oral linezolid compared with intravenous vancomycin for the treatment of methicillin-resistant Staphylococcus aureus-complicated skin and soft tissue infections: a retrospective, propensity score-matched, case-control analysis. Clin Ther. 2012;34:1667–73.PubMedCrossRef
46.
Itani KM, Dryden MS, Bhattacharyya H, Kunkel MJ, Baruch AM, Weigelt JA. Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft-tissue infections proven to be caused by methicillin-resistant Staphylococcus aureus. Am J Surg. 2010;199:804–16.PubMedCrossRef
47.
Fowler VG Jr, Boucher HW, Corey GR, Abrutyn E, Karchmer AW, Rupp ME, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med. 2006;355:653–65.PubMedCrossRef
48.
Leu WJ, Liu YC, Wang HW, Chien HY, Liu HP, Lin YM. Evaluation of a vancomycin dosing nomogram in achieving high target trough concentrations in Taiwanese patients. Int J Infect Dis. 2012;16:e804–10.PubMedCrossRef
49.
Ingram PR, Lye DC, Tambyah PA, Goh WP, Tam VH, Fisher DA. Risk factors for nephrotoxicity associated with continuous vancomycin infusion in outpatient parenteral antibiotic therapy. J Antimicrob Chemother. 2008;62:168–71.PubMedCrossRef
50.
Ingram PR, Lye DC, Fisher DA, Goh WP, Tam VH. Nephrotoxicity of continuous versus intermittent infusion of vancomycin in outpatient parenteral antimicrobial therapy. Int J Antimicrob Agents. 2009;34:570–4.PubMedCrossRef
51.
Hutschala D, Kinstner C, Skhirdladze K, Thalhammer F, Müller M, Tschernko E. Influence of vancomycin on renal function in critically ill patients after cardiac surgery: continuous versus intermittent infusion. Anesthesiology. 2009;111:356–65.PubMedCrossRef
52.
Cataldo MA, Tacconelli E, Grilli E, Pea F, Petrosillo N. Continuous versus intermittent infusion of vancomycin for the treatment of gram-positive infections: systematic review and meta-analysis. J Antimicrob Chemother. 2012;67:17–24.PubMedCrossRef
53.
Vuagnat A, Stern R, Lotthe A, Schuhmacher H, Duong M, Hoffmeyer P, et al. High dose vancomycin for osteomyelitis: continuous vs. intermittent infusion. J Clin Pharm Ther. 2004;29:351–7.PubMedCrossRef
54.
Healy DP, Sahai JV, Fuller SH, Polk RE. Vancomycin-induced histamine release and “red man syndrome”: comparison of 1- and 2-hour infusions. Antimicrob Agents Chemother. 1990;34:550–4.PubMedCrossRef
55.
Healy DP, Polk RE, Garson ML, Rock DT, Comstock TJ. Comparison of steady-state pharmacokinetics of two dosage regimens of vancomycin in normal volunteers. Antimicrob Agents Chemother. 1987;31:393–7.PubMedCrossRef
56.
van Hal SJ, Paterson DL, Lodise TP. Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter. Antimicrob Agents Chemother. 2013;57:734–44.PubMedCrossRef
57.
Hazlewood KA, Brouse SD, Pitcher WD, Hall RG. Vancomycin-associated nephrotoxicity: grave concern or death by character assassination? Am J Med. 2010;123:182.e1–7.
58.
Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med. 2006;166:2138–44.PubMedCrossRef
59.
Wang JT, Fang CT, Chen YC, Chang SC. Necessity of a loading dose when using vancomycin in critically ill patients. J Antimicrob Chemother. 2001;47:246.PubMedCrossRef
60.
Li J, Udy AA, Kirkpatrick CM, Lipman J, Roberts JA. Improving vancomycin prescription in critical illness through a drug use evaluation process: a weight-based dosing intervention study. Int J Antimicrob Agents. 2012;39:69–72.PubMedCrossRef
61.
Truong J, Levkovich BJ, Padiglione AA. Simple approach to improving vancomycin dosing in intensive care: a standardised loading dose results in earlier therapeutic levels. Intern Med J. 2012;42:23–9.PubMedCrossRef
62.
Thomson AH, Staatz CE, Tobin CM, Gall M, Lovering AM. Development and evaluation of vancomycin dosage guidelines designed to achieve new target concentrations. J Antimicrob Chemother. 2009;63:1050–7.PubMedCrossRef
63.
Soriano A, Marco F, Martínez JA, Pisos E, Almela M, Dimova VP, et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis. 2008;46:193–200.PubMedCrossRef
64.
Takesue Y, Nakajima K, Takahashi Y, Ichiki K, Ishihara M, Wada Y, et al. Clinical characteristics of vancomycin minimum inhibitory concentration of 2 μg/ml methicillin-resistant Staphylococcus aureus strains isolated from patients with bacteremia. J Infect Chemother. 2011;17:52–7.PubMedCrossRef
65.
van Hal SJ, Lodise TP, Paterson DL. The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis. Clin Infect Dis. 2012;54:755–71.PubMedCrossRef
66.
Lodise TP, Graves J, Evans A, Graffunder E, Helmecke M, Lomaestro BM, et al. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother. 2008;52:3315–20.PubMedCrossRef
67.
Moise PA, Sakoulas G, Forrest A, Schentag JJ. Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother. 2007;51:2582–6.PubMedCrossRef
68.
Wang JL, Wang JT, Sheng WH, Chen YC, Chang SC. Nosocomial methicillin-resistant Staphylococcus aureus (MRSA) bacteremia in Taiwan: mortality analyses and the impact of vancomycin, MIC = 2 mg/L, by the broth microdilution method. BMC Infect Dis. 2010;10:159.PubMedCrossRef
69.
Alós JI, García-Cañas A, García-Hierro P, Rodríguez-Salvanés F. Vancomycin MICs did not creep in Staphylococcus aureus isolates from 2002 to 2006 in a setting with low vancomycin usage. J Antimicrob Chemother. 2008;62:773–5.PubMedCrossRef
70.
Steinkraus G, White R, Friedrich L. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001–05. J Antimicrob Chemother. 2007;60:788–94.PubMedCrossRef
71.
Sader HS, Fey PD, Limaye AP, Madinger N, Pankey G, Rahal J, et al. Evaluation of vancomycin and daptomycin potency trends (MIC creep) against methicillin-resistant Staphylococcus aureus isolates collected in nine U.S. medical centers from 2002 to 2006. Antimicrob Agents Chemother. 2009;53:4127–32.
72.
Sakoulas G, Moellering RC Jr. Increasing antibiotic resistance among methicillin-resistant Staphylococcus aureus strains. Clin Infect Dis. 2008;46(suppl 5):S360–7.PubMedCrossRef
73.
Hsu DI, Hidayat LK, Quist R, Hindler J, Karlsson A, Yusof A, et al. Comparison of method-specific vancomycin minimum inhibitory concentration values and their predictability for treatment outcome of meticillin-resistant Staphylococcus aureus (MRSA) infections. Int J Antimicrob Agents. 2008;32:378–85.PubMedCrossRef
74.
Prakash V, Lewis JS 2nd, Jorgensen JH. Vancomycin MICs for methicillin-resistant Staphylococcus aureus isolates differ based upon the susceptibility test method used. Antimicrob Agents Chemother. 2008;52:4528.PubMedCrossRef
75.
Sader HS, Rhomberg PR, Jones RN. Nine-hospital study comparing broth microdilution and Etest method results for vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2009;53:3162–5.PubMedCrossRef
76.
Fridkin SK, Hageman J, McDougal LK, Mohammed J, Jarvis WR, Perl TM, et al. Vancomycin-intermediate Staphylococcus aureus Epidemiology Study Group. Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997–2001. Clin Infect Dis. 2003;36:429–39.PubMedCrossRef
77.
Tenover FC, Moellering RC Jr. The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin Infect Dis. 2007;44:1208–15.PubMedCrossRef
78.
Cui L, Tominaga E, Neoh HM, Hiramatsu K. Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate staphylococcus aureus. Antimicrob Agents Chemother. 2006;50:1079–82.PubMedCrossRef
79.
Kelley PG, Gao W, Ward PB, Howden BP. Daptomycin non-susceptibility in vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous-VISA (hVISA): implications for therapy after vancomycin treatment failure. J Antimicrob Chemother. 2011;66:1057–60.PubMedCrossRef
80.
Crompton JA, North DS, Yoon M, Steenbergen JN, Lamp KC, Forrest GN. Outcomes with daptomycin in the treatment of Staphylococcus aureus infections with a range of vancomycin MICs. J Antimicrob Chemother. 2010;65:1784–91.PubMedCrossRef
81.
Moore CL, Osaki-Kiyan P, Haque NZ, Perri MB, Donabedian S, Zervos MJ. Daptomycin versus vancomycin for bloodstream infections due to methicillin-resistant Staphylococcus aureus with a high vancomycin minimum inhibitory concentration: a case-control study. Clin Infect Dis. 2012;54:51–8.PubMedCrossRef
82.
Moellering RC Jr, Krogstad DJ, Greenblatt DJ. Vancomycin therapy in patients with impaired renal function: a nomogram for dosage. Ann Intern Med. 1981;94:343–6.PubMedCrossRef
83.
Matzke GR, McGory RW, Halstenson CE, Keane WF. Pharmacokinetics of vancomycin in patients with various degrees of renal function. Antimicrob Agents Chemother. 1984;25:433–7.PubMedCrossRef
84.
Kullar R, Leonard SN, Davis SL, Delgado G Jr, Pogue JM, Wahby KA, et al. Validation of the effectiveness of a vancomycin nomogram in achieving target trough concentrations of 15–20 mg/L suggested by the vancomycin consensus guidelines. Pharmacotherapy. 2011;31:441–8.PubMedCrossRef
85.
Pollard TA, Lampasona V, Akkerman S, Tom K, Hooks MA, Mullins RE, et al. Vancomycin redistribution: dosing recommendations following high-flux hemodialysis. Kidney Int. 1994;45:232–7.PubMedCrossRef
86.
Clark WR, Leypoldt JK, Henderson LW, Mueller BA, Scott MK, Vonesh EF. Quantifying the effect of changes in the hemodialysis prescription on effective solute removal with a mathematical model. J Am Soc Nephrol. 1999;10:601–9.PubMed
87.
DeSoi CA, Sahm DF, Umans JG. Vancomycin elimination during high-flux hemodialysis: kinetic model and comparison of four membranes. Am J Kidney Dis. 1992;20:354–60.PubMed
88.
Böhler J, Reetze-Bonorden P, Keller E, Kramer A, Schollmeyer PJ. Rebound of plasma vancomycin levels after haemodialysis with highly permeable membranes. Eur J Clin Pharmacol. 1992;42:635–9.PubMedCrossRef
89.
Pollard TA, Lampasona V, Akkerman S, Tom K, Hooks MA, Mullins RE, et al. Vancomycin redistribution: dosing recommendations following high-flux hemodialysis. Kidney Int. 1994;45:232–7.PubMedCrossRef
90.
Barth RH, DeVincenzo N. Use of vancomycin in high-flux hemodialysis: experience with 130 courses of therapy. Kidney Int. 1996;50:929–36.PubMedCrossRef
91.
Brown M, Polisetty R, Gracely EJ, Cuhaci B, Schlecht HP. Weight-based loading of vancomycin in patients on hemodialysis. Clin Infect Dis. 2011;53:164–6.PubMedCrossRef
92.
Vandecasteele SJ, De Bacquer D, De Vriese AS. Implementation of a dose calculator for vancomycin to achieve target trough levels of 15–20 microg/ml in persons undergoing hemodialysis. Clin Infect Dis. 2011;53:124–9.PubMedCrossRef
93.
Crawford BS, Largen RF, Walton T, Doran JJ. Once-weekly vancomycin for patients receiving high-flux hemodialysis. Am J Health Syst Pharm. 2008;65:1248–53.PubMedCrossRef
94.
Roberts JA, Kruger P, Paterson DL, Lipman J. Antibiotic resistance–what’s dosing got to do with it? Crit Care Med. 2008;36:2433–40.PubMedCrossRef
95.
Gatward JJ, Gibbon GJ, Wrathall G, Padkin A. Renal replacement therapy for acute renal failure: a survey of practice in adult intensive care units in the United Kingdom. Anaesthesia. 2008;63:959–66.PubMedCrossRef
96.
RENAL Study Investigators. Renal replacement therapy for acute kidney injury in Australian and New Zealand intensive care units: a practice survey. Crit Care Resusc. 2008;10:225–30.
97.
Trotman RL, Williamson JC, Shoemaker DM, Salzer WL. Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy. Clin Infect Dis. 2005;41:1159–66.PubMedCrossRef
98.
Joy MS, Matzke GR, Frye RF, Palevsky PM. Determinants of vancomycin clearance by continuous venovenous hemofiltration and continuous venovenous hemodialysis. Am J Kidney Dis. 1998;31:1019–27.PubMedCrossRef
99.
Chaijamorn W, Jitsurong A, Wiwattanawongsa K, Wanakamanee U, Dandecha P. Vancomycin clearance during continuous venovenous haemofiltration in critically ill patients. Int J Antimicrob Agents. 2011;38:152–6.PubMedCrossRef
100.
DelDot ME, Lipman J, Tett SE. Vancomycin pharmacokinetics in critically ill patients receiving continuous venovenous haemodiafiltration. Br J Clin Pharmacol. 2004;58:259–68.PubMedCrossRef
101.
Yamamoto T, Yasuno N, Katada S, Hisaka A, Hanafusa N, Noiri E, et al. Proposal of a pharmacokinetically optimized dosage regimen of antibiotics in patients receiving continuous hemodiafiltration. Antimicrob Agents Chemother. 2011;55:5804–12.PubMedCrossRef
102.
Hirasawa H, Oda S, Nakamura M, Watanabe E, Shiga H, Matsuda K. Continuous hemodiafiltration with a cytokine-adsorbing hemofilter for sepsis. Blood Purif. 2012;34:164–70.PubMedCrossRef
103.
Morse GD, Farolino DF, Apicella MA, Walshe JJ. Comparative study of intraperitoneal and intravenous vancomycin pharmacokinetics during continuous ambulatory peritoneal dialysis. Antimicrob Agents Chemother. 1987;31:173–7.PubMedCrossRef
104.
Wiggins KJ, Craig JC, Johnson DW, Strippoli GFM. Treatment for peritoneal dialysis-associated peritonitis. London: The Cochrane Library; 2010.
105.
Montañés Pauls B, Almiñana MA, Casabó Alós VG. Vancomycin pharmacokinetics during continuous ambulatory peritoneal dialysis in patients with peritonitis. Eur J Pharm Sci. 2011;43:212–6.
106.
Li PK, Szeto CC, Piraino B, Bernardini J, Figueiredo AE, Gupta A, et al. Peritoneal dialysis-related infections recommendations: 2010 update. Perit Dial Int. 2010;30:393–423.PubMedCrossRef
107.
Bunke CM, Aronoff GR, Brier ME, Sloan RS, Luft FC. Vancomycin kinetics during continuous ambulatory peritoneal dialysis. Clin Pharmacol Ther. 1983;34:631–7.PubMedCrossRef
108.
Manley HJ, Bailie GR, Frye RF, McGoldrick MD. Intravenous vancomycin pharmacokinetics in automated peritoneal dialysis patients. Perit Dial Int. 2001;21:378–85.PubMed
109.
Broome L, So TY. An evaluation of initial vancomycin dosing in infants, children, and adolescents. Int J Pediatr. 2011 (Epub ahead of print).
110.
Kim DI, Im MS, Choi JH, Lee J, Choi EH, Lee HJ. Therapeutic monitoring of vancomycin according to initial dosing regimen in pediatric patients. Korean J Pediatr. 2010;53:1000–5.PubMedCrossRef
111.
Eiland LS, English TM, Eiland EH 3rd. Assessment of vancomycin dosing and subsequent serum concentrations in pediatric patients. Ann Pharmacother. 2011;45:582–9.PubMedCrossRef
112.
Frymoyer A, Hersh AL, Benet LZ, Guglielmo BJ. Current recommended dosing of vancomycin for children with invasive methicillin-resistant Staphylococcus aureus infections is inadequate. Pediatr Infect Dis J. 2009;28:398–402.PubMedCrossRef
113.
Glover ML, Cole E, Wolfsdorf J. Vancomycin dosage requirements among pediatric intensive care unit patients with normal renal function. J Crit Care. 2000;15:1–4.PubMedCrossRef
114.
McCabe T, Davis G, Iocono J, Nelson C, Kuhn R. Evaluating the empiric dose of vancomycin in pediatric patients (abstract). J Pediatr Pharmacol Ther. 2009;14:168.
115.
Gordon CL, Thompson C, Carapetis JR, Turnidge J, Kilburn C, Currie BJ. Trough concentrations of vancomycin: adult therapeutic targets are not appropriate for children. Pediatr Infect Dis J. 2012;31:1269–71.PubMedCrossRef
116.
Frymoyer A, Guglielmo BJ, Wilson SD, Scarpace SB, Benet LZ, Hersh AL. Impact of a hospitalwide increase in empiric pediatric vancomycin dosing on initial trough concentrations. Pharmacotherapy. 2011;31:871–6.PubMedCrossRef
Metadata
Title
Practice guidelines for therapeutic drug monitoring of vancomycin: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring
Authors
Kazuaki Matsumoto
Yoshio Takesue
Norio Ohmagari
Takahiro Mochizuki
Hiroshige Mikamo
Masafumi Seki
Shunji Takakura
Issei Tokimatsu
Yoshiko Takahashi
Kei Kasahara
Kenji Okada
Masahiro Igarashi
Masahiro Kobayashi
Yukihiro Hamada
Masao Kimura
Yoshifumi Nishi
Yusuke Tanigawara
Toshimi Kimura
Publication date
01-06-2013
Publisher
Springer Japan
Published in
Journal of Infection and Chemotherapy / Issue 3/2013
Print ISSN: 1341-321X
Electronic ISSN: 1437-7780
DOI
https://doi.org/10.1007/s10156-013-0599-4

Other articles of this Issue 3/2013

Journal of Infection and Chemotherapy 3/2013 Go to the issue

Original Article

Nationwide survey of the development of drug resistance in the pediatric field in 2007 and 2010: drug sensitivity of Haemophilus influenzae in Japan (second report)

Original Article

Antibiotic susceptibility in relation to genotype of Streptococcus pneumoniae, Haemophilus influenzae, and Mycoplasma pneumoniae responsible for community-acquired pneumonia in children

Note

Influence of smoking on HIV infection among HIV-infected Japanese men

Case Report

Multiple liver cyst infection caused by Salmonella ajiobo in autosomal dominant polycystic kidney disease

Original Article

Good transfer of tebipenem into middle ear effusion conduces to the favorable clinical outcomes of tebipenem pivoxil in pediatric patients with acute otitis media

Note

Is paromomycin the drug of choice for eradication of Blastocystis in adults?

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24 to hear Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits